NDA 214511 · Lumicell
Lumisight
Pegulicianine Acetate · Intravenous
NovelPriority reviewCDER novel approval, Apr 17, 2024: To use as an optical imaging agent for the detection of cancerous tissue
Last checked: Nov 19, 2026Latest source record: Apr 17, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Apr 17, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
8
4 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ANAPHYLAXIS AND OTHER SERIOUS HYPERSENSITIVITY REACTIONS Serious hypersensitivity reactions, including anaphylaxis, can occur during or following administration of LUMISIGHT. Anaphylaxis occurred in 4/726 (0.6%) of patients in clinical studies. Signs and symptoms associated with other hypersensitivity reactions included pruritus, urticaria, hypotension, lip swelling, erythema, anxiety, chest pain, cyanosis, dizziness, dyspnea, headache, hypoesthesia, hyperventilation, maculopapular rash, nausea, paresthesia, visual changes, and vomiting. Before LUMISIGHT administration, assess all patients for any history of hypersensitivity reaction to contrast media or products containing polyethylene glycol (PEG). Always have emergency resuscitation drugs, equipment, and trained personnel promptly available. Monitor all patients for hypersensitivity reactions. If a hypersensitivity reaction...
What it is approved for
From the label in effect Jan 9, 2026.
LUMISIGHT is indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery. LUMISIGHT is an optical imaging agent indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery. ( 1 )
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 17, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
- LUMISIGHT · PEGULICIANINE ACETATE EQ 39MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pegulicianine" as an intervention, any sponsor and status, largest first.
- Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery PlaquesNot yet recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06957821 · 25 participants (planned) · Start Jun 2027 · Primary completion Jul 2028
Drug: Pegulicianine · For: Carotid Artery Diseases; Peripheral Arterial Disease
Sites: Boston, Massachusetts
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- flushing4
- hypersensitivity3
- paraesthesia3
- anaphylactic shock2
- back pain2
- cardiac arrest2
- cough2
- feeling hot2
- hyperhidrosis2
- malaise2
- nausea2
- acute kidney injury1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 2 |
| 2026 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery.
Smith BL, Hunt KK, Carr D, et al. · NEJM Evid 2023 · Clinical Trial, Research Support, N.I.H., Extramural
- Clinical Impact of Intraoperative Margin Assessment in Breast-Conserving Surgery With a Novel Pegulicianine Fluorescence-Guided System: A Nonrandomized Controlled Trial.
Hwang ES, Beitsch P, Blumencranz P, et al. · JAMA Surg 2022 · Controlled Clinical Trial, Multicenter Study
Sponsor: Lumicell
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.